Product Description
Intended for use in FGFR2/3 driven advanced solid tumors. (Sourced from: https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Yahong Pharmaceutical Technology
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20255196 |
CTR20255196 | P1 |
Unknown |
Oncology Solid Tumor Unspecified |
None |
2026-01-25 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|